TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01220765

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capnography
Description: In the capnography arm, respiratory monitoring is performed with pulse oximetry and capnography. If the capnogram indicates sub-optimal ventilation and/or apnea, denoted as a flat line on the capnometer for ≥ 15 seconds, a respiratory rate ≤ 6, or a end-tidal CO2 \> 50 mmHg, medical staff will intervene by arousing the patient, performing chinlift or jawthrust, abandon from giving additional propofol, or provision of oxygen. The nurse qualified in sedation management will assess capnography him/ herself.
Study: NCT01865669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin, 10-10mol/L to 10-5mol/L
Study: NCT04586738

Intervention type: PROCEDURE
Group type: OTHER
Intervention: non-perforating deep sclerectomy surgery
Description: Non-penetrating deep sclerectomy is a non-perforating filtration procedure used for the surgical treatment of medically uncontrolled open angle glaucoma.This surgery is performed to facilitate the outflow of aqueous humour from the anterior chamber to the subconjunctival space through a natural membrane (trabeculo-Descemet's window). This enables a more physiological reduction of intraocular pressure to be achieved.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: non-perforating deep sclerectomy surgery
Description: Non-penetrating deep sclerectomy is a non-perforating filtration procedure used for the surgical treatment of medically uncontrolled open angle glaucoma.This surgery is performed to facilitate the outflow of aqueous humour from the anterior chamber to the subconjunctival space through a natural membrane (trabeculo-Descemet's window). This enables a more physiological reduction of intraocular pressure to be achieved.
Study: NCT04015076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inzomelid
Description: Active Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inzomelid
Description: Active Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inzomelid
Description: Active Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to Match

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to Match
Study: NCT01913431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baracle Tab.®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baraclude Tab.®
Study: NCT03534765

Intervention type: DIAGNOSTIC_TEST
Intervention: CT abdomen +/- pelvis
Description: Diagnostic CT scan (only if requested by responsible clinicians)

Intervention type: DIAGNOSTIC_TEST
Intervention: CT abdomen +/- pelvis
Description: Diagnostic CT scan (only if requested by responsible clinicians)

Intervention type: DIAGNOSTIC_TEST
Intervention: Edmunton Frailty Score
Description: Patient completed previously valided questionnaire quantifying frailty.

Intervention type: PROCEDURE
Intervention: Emergency laparotomy for general surgical pathology
Description: Emergency general surgical laparotomy (defined by the UK NELA body)

Intervention type: PROCEDURE
Intervention: Emergency laparotomy for general surgical pathology
Description: Emergency general surgical laparotomy (defined by the UK NELA body)
Study: NCT01392222

Intervention type: BEHAVIORAL
Intervention: Focus groups
Description: The focus groups will cover the following issues~* Perceptions of thyroid cancer and disease status~* Sources of information used in papillary microcarcinoma treatment decision-making~* Treatment decision-making processes and influential factors~* Perceived barriers to active surveillance to treat papillary microcarcinoma (for the immediate surgery sub-sample)~* Perceived facilitators to active surveillance to treat papillary microcarcinoma (for the non-immediate surgery sub-sample)~* Views about how to improve acceptability of active surveillance as a disease management option

Intervention type: BEHAVIORAL
Intervention: Focus groups
Description: The focus groups will cover the following issues:~* Perceptions of thyroid cancer and disease status~* Sources of information used in papillary microcarcinoma treatment decision-making~* Treatment decision-making processes and influential factors~* Perceived barriers to active surveillance to treat papillary microcarcinoma (for the immediate surgery sub-sample)~* Perceived facilitators to active surveillance to treat papillary microcarcinoma (for the non-immediate surgery sub-sample)~* Views about how to improve acceptability of active surveillance as a disease management option
Study: NCT04692844

Intervention type: DRUG
Intervention: Propranolol
Description: Patients will receive Propranolol in the course of their routine treatment. Results will be used to explore biological phenomena or disease processes.

Intervention type: DRUG
Intervention: Primidone
Description: Patients will receive Primidone in the course of their routine treatment. Results will be used to explore biological phenomena or disease processes.
Study: NCT03218332

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarkers for detecting possible CTE invivo
Description: Detection biomarkers for possible CTE: Imaging/blood/CSF/PET-tau/MRI/europsychological assessment

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarkers for detecting possible CTE invivo
Description: Detection biomarkers for possible CTE: Imaging/blood/CSF/PET-tau/MRI/europsychological assessment
Study: NCT03048084

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: Antiepileptic drug levetiracetam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic Acid
Description: Antiepileptic drug valproic acid
Study: NCT02532959

Intervention type: DEVICE
Intervention: Diagnostic Breath Analysis
Description: Conduct exhaled breath samples
Study: NCT02687412

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pre-operative assessment, counseling and education
Description: pre-operative assessment, counseling and FT management education

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative nutritional drink up to 4 h prior to surgery
Description: Preoperative nutritional drink up to 4 h prior to surgery mechanical bowl preparation should not be used

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bowel preparation
Description: patients are not received mechanical bowel preparation, only oral intestinal cleaner 12 h pre-operation can be accepted, but no need of liquid stool

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: preoperative treatment with carbohydrates
Description: preoperative treatment with carbohydrates (patients without diabetes).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fast solid
Description: fast solid food before 6 h and liquid food Intake of clear fluids 2 h before anaesthesia;

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: avoiding hypothermia
Description: avoiding hypothermia, keeping the intra-operative lowtemperature at 36 ±0.5 degree centigrade; antiemetics at end of anaesthesia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative glycaemic control
Description: Postoperative glycaemic control;

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: postoperative nausea and vomiting (PONV) control;

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: early postoperative diet
Description: early postoperative diet(3-6 h after surgery, patients resumed a liquid diet, 12 h after surgery patients began to take solid diet).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: pre-operative fasting at least 8h

Intervention type: PROCEDURE
Group type: OTHER
Intervention: bowel preparation for traditional surgery
Description: Oral bowel preparations or mechanical bowl until liquid stool

Intervention type: PROCEDURE
Group type: OTHER
Intervention: began to take solid diet after anal exhaust
Description: 6 h after surgery, patients resumed a liquid diet, patients began to take solid diet after anal exhaust
Study: NCT04071977

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined antioxidant therapy
Description: It consists of a tablet with lutein (10 mg), astaxanthin (4 mg), Zeaxanthin (1 mg), vitamin C (L-ascorbic acid 180 mg), vitamin E (DL-alpha tocopherol 30 mg), zinc (zinc oxide 20 mg), copper (copper sulfate 1 mg), taken once a day for 12 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It consists in a capsule with 100 mg of magnesium oxide
Study: NCT02931890

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 3 weekly course of docetaxel i.v in arm 1 and 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 3 weekly course of docetaxel i.v in arm 1 and 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 3 weekly course oxaliplatin as a 2 hr i.v. in arm 1 and 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 3 weekly course oxaliplatin as a 2 hr i.v. in arm 1 and 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: oral capecitabine in arm 1 and 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: oral capecitabine in arm 1 and 2

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastrectomy
Description: resection of gastric cancer after pre-operative chemotherapy for all arms

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastrectomy
Description: resection of gastric cancer after pre-operative chemotherapy for all arms

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastrectomy
Description: resection of gastric cancer after pre-operative chemotherapy for all arms

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy of gastric cancer
Description: 5 weeks of radiation, 5 times a week with a total of 45 Gy (in arm 2 and 3)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy of gastric cancer
Description: 5 weeks of radiation, 5 times a week with a total of 45 Gy (in arm 2 and 3)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 5 weeks of paclitaxel i.v once a week (in arm 2 and 3)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 5 weeks of paclitaxel i.v once a week (in arm 2 and 3)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: 5 weeks of carboplatin i.v once a week (in arm 2 and 3)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: 5 weeks of carboplatin i.v once a week (in arm 2 and 3)
Study: NCT02354924

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofinity soft contact lens
Description: Biofinity soft contact lens on two eyes and follow up for 3 months (90 days). It is necessary to remove contact lenses every day and replace after 30 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visco soft contact lens
Description: Viso soft contact lens on two eyes and follow up for 3 months (90 days). It is necessary to remove contact lenses every day and replace after 30 days.
Study: NCT03707444

Intervention type: DEVICE
Intervention: Scrambler Therapy Device
Description: Superficial neuromodulation using EKG type electrodes \[Scrambler (MC5-A Calmare) Therapy\]
Study: NCT00657514

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: 500mg tablet po bid up to 1000mg (2 500mg tablets) po bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet po bid up to 2 tablets po bid if tolerated
Study: NCT00235443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lacosamide
Description: Open-label treatment (two times per day) with film-coated tablets include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, and 600mg/day throughout individual study period.
Study: NCT01547520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meperidine
Description: intramuscular, 25 mg, 5 to 10 minutes before EGD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 25 ml of normal saline, intramuscular, 5 to 10 minutes before EGD
Study: NCT04394520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Introduction
Description: A variation in the introductory content to motivate participants to complete the survey. Participants will be presented with modified introductory language based on the findings from local focus groups and key informant interviews.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Introduction
Description: A variation in the introductory content to motivate participants to complete the survey. Participants will be presented with modified introductory language based on the findings from local focus groups and key informant interviews.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Introduction
Description: A variation in the introductory content to motivate participants to complete the survey. Participants will be presented with modified introductory language based on the findings from local focus groups and key informant interviews.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Introduction
Description: A variation in the introductory content to motivate participants to complete the survey. Participants will be presented with modified introductory language based on the findings from local focus groups and key informant interviews.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Opt-in
Description: A variation in the consent mode to motivate participants to complete the survey. Participants will be given the choice to actively opt-in to the survey, if they do not respond, the survey will terminate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Opt-out
Description: A variation in the consent mode to motivate participants to complete the survey. Participants will be given the choice to actively opt-out to the survey, if they do not respond, the survey will continue.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Opt-in
Description: A variation in the consent mode to motivate participants to complete the survey. Participants will be given the choice to passively opt-in to the survey, if they do not hang-up, the survey will continue.
Study: NCT03431051

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Beverage Initiative
Description: A Healthy Beverage Initiative will be instituted at two hospital campuses.
Study: NCT01176604

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Yttrium Y 90 Glass Microspheres
Description: Given via catheter
Study: NCT02814474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Na-3-hydroxybutyrate
Description: Infusion of Na-3-hydroxybutyrate (0.18 g/kg/hour) for 390 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Infusion of 0.9 % saline
Study: NCT01045122

Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: For propofol, the current study will employ the Marsh parameters, with an initial effect site target concentration of 1.0 mcg/ml, a level likely to produce only mild sedation. Though our patient population is expected to be predominantly obese, a previous pharmacokinetic study has validated that constant infusions utilizing the dosing scheme of mcg-1•kg-1•min will yield similar effect site concentrations.25 The effect site target will be increased in increments approximately every five minutes until the pharmacodynamic targets defined in the study are attained.

Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine
Description: For dexmedetomidine, an intravenous loading dose of 0.5 mcg/kg will be infused over 10 minutes and followed by an infusion starting at 0.5 mcg/kg/hr. This infusion will be titrated up to a maximum of 1.2 mcg/kg/hr.
Study: NCT00997724

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: a-VATS
Description: In brief, general anesthesia with selective lung ventilation was performed with the use of a double-lumen endotracheal tube. When postoperative mechanical ventilation was necessary, a standard endotracheal tube was substituted for the double-lumen tube. Patients were placed in the lateral decubitus position. Two thoracoports were placed in the sixth or seventh intercostal space (ICS) on the anterior axillary line and in the seventh or eighth ICS on the posterior axillary line; an anterolateral minithoracotomy (7 cm) was made in the fourth ICS for an upper lobectomy or in the fifth ICS for a middle or lower lobectomy.
Study: NCT01526811

Intervention type: DEVICE
Intervention: Endurant Stent graft
Description: Endurant Stent graft implantation
Study: NCT03678259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 124I-p5+14 Injection
Description: 124I-p5+14 Injection which is a formulation of a synthetic, all natural, 45 amino acid peptide (MW = 4766.4) with a net +12 positive charge
Study: NCT03710213

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message-based Intervention
Description: The intervention consists of a series of educational and reminder text messages that a patient will receive in the week prior to a scheduled colonoscopy, in addition to two text messages at the time of enrollment explaining the texting program.
Study: NCT00468442

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Pancreatic Islet Cells
Description: transplant of islet cells injected into the portal vein of the liver

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin
Description: Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.
Study: NCT02280057

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 1500 mg (=2 pills) per day in six months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 pills per day in six months; pills look like metformin pills
Study: NCT03239873

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VARIVAX® PE34 Process
Description: Varicella virus vaccine live manufactured with a new passage extension process (PE34)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VARIVAX® 2016 Commercial Process
Description: Varicella virus vaccine live manufactured with the 2016 commercial process

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-M-R II®
Description: Measles, Mumps, and Rubella virus vaccine live

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-M-R II®
Description: Measles, Mumps, and Rubella virus vaccine live
Study: NCT01365533

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: Roflumilast 500 μg, one tablet once daily, orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, one tablet once daily, orally
Study: NCT00468442

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daclizumab
Description: Will replace antithymocyte globulin in all islet transplantations after the first one

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Depletes transient B-cells
Study: NCT03369184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen gas
Description: The intervention is administered as previously described. The duration of intervention is 10 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Ambient air
Description: Administered similarly to treatment arm, via an open face mask and during 10 minutes
Study: NCT02760758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDI-31244
Description: NNI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDI-31244
Description: NNI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDI-31244
Description: NNI
Study: NCT00468442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Maintenance immunosuppressive therapy
Study: NCT03761758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacle lenses
Description: Spectacle lenses with clear central apertures

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacle lenses
Description: Spectacle lenses with clear central apertures

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacle lenses
Description: Spectacle lenses with clear central apertures
Study: NCT02760758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDI-31244
Description: NNI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDI-31244
Description: NNI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDI-31244
Description: NNI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDI-31244
Description: NNI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDI-31244
Description: NNI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDI-31244
Description: NNI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDI-31244
Description: NNI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDI-31244
Description: NNI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: no active ingredients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: no active ingredients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: no active ingredients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: no active ingredients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: no active ingredients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: no active ingredients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: no active ingredients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: no active ingredients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: no active ingredients
Study: NCT01054300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 2 mg single dose
Description: Ertugliflozin 2 mg dose (two 1 mg strength tablets), administered as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 2 mg single dose
Description: Ertugliflozin 2 mg dose (two 1 mg strength tablets), administered as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 2 mg split into twice daily
Description: Ertugliflozin 1 mg dose (1 mg strength tablet) administered twice daily x 1 day
Study: NCT02760758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: no active ingredients